Key facts
- This page summarizes Anthony J. Guzzo's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jan 2022, 17:49.
Anthony J. Guzzo - 19 Jan 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- VP, Chief Accounting Officer
- Issuer ticker
- PHAT
- Reported as of
- 19 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2022, 17:49:43 UTC
- Prior SEC filing
- 11 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Larry Miller, Attorney-in-Fact for Anthony J. Guzzo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anthony J. Guzzo filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 21 Jan 2022.
Change
- Previous filing in this sequence was filed on 11 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHAT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,000
- Change %
- +250%
- Price
- $0.000000
- Shares after
- 8,399
- Date
- 19 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
PHAT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 464
- Date
- 19 Jan 2022
- Ownership
- by 401(k)
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHAT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 19 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $15.21
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Footnote F2
Includes 2,399 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022.
Footnote F3
The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.